Molecular profiling for early patient identification — 1 of 2

Molecular profiling and biomarker-targeted therapy are transforming
patient care in CCA

Genomic studies reveal that ~50% of patients with CCA have actionable alterations, including FGFR2 fusions or rearrangements16

ACTIONABLE ALTERATIONS IN iCCA16-21*

Labelling line Labelling line Labelling line

No potentially
targetable
genomic
alteration
identified

FGFR2 fusions:
10–16%

IDH mutations:
18–36%

KRAS, BRAF, MSI-H,
NTRK, EGFR and other
alterations

FGFR2 fusions or rearrangements are the most common FGFR alteration, occurring almost exclusively in iCCA, and have been identified in 10⁠–⁠16% of iCCA cases1

FGFR2 fusions are detectable early in disease progression and are key drivers of tumour growth. Molecular profiling is necessary to identify FGFR2 fusions or rearrangements22,23

*Percentages reported for individual alterations are from different primary analyses and are not all drawn from a single population of patients with iCCA. Although FGFR2 fusions and IDH mutations tend to be mutually exclusive in iCCA, mutations in the "other alterations" category can be found in tumours that also carry other potentially targetable mutations or genetic alterations.20